JP2022530322A5 - - Google Patents
Info
- Publication number
- JP2022530322A5 JP2022530322A5 JP2021559917A JP2021559917A JP2022530322A5 JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5 JP 2021559917 A JP2021559917 A JP 2021559917A JP 2021559917 A JP2021559917 A JP 2021559917A JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- solvate
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835963P | 2019-04-18 | 2019-04-18 | |
| US62/835,963 | 2019-04-18 | ||
| PCT/IB2020/000288 WO2020212755A1 (en) | 2019-04-18 | 2020-04-16 | Compounds and methods for the treatment of ocular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530322A JP2022530322A (ja) | 2022-06-29 |
| JP2022530322A5 true JP2022530322A5 (cg-RX-API-DMAC10.html) | 2024-03-26 |
| JP7700045B2 JP7700045B2 (ja) | 2025-06-30 |
Family
ID=72837744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559917A Active JP7700045B2 (ja) | 2019-04-18 | 2020-04-16 | 眼障害を処置するための化合物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10875845B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3955926A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7700045B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220003555A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114025759A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020259996B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3137583A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL287264A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020212755A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN116635032A (zh) * | 2020-10-21 | 2023-08-22 | 阿祖拉眼科有限公司 | 用于治疗眼部病症的化合物和方法 |
| EP4232458A4 (en) * | 2020-10-21 | 2024-10-02 | Azura Ophthalmics Ltd | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2023067387A2 (en) * | 2021-10-20 | 2023-04-27 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of dermal and ocular disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040005641A1 (en) | 2002-02-15 | 2004-01-08 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2004287875B2 (en) * | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP3632444A3 (en) * | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2877465A4 (en) * | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
| EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| CA3020713A1 (en) * | 2016-04-19 | 2017-10-26 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| US11420995B2 (en) | 2017-03-03 | 2022-08-23 | Synovo Gmbh | Anti-infective and anti-inflammatory compounds |
| CA3057569A1 (en) | 2017-03-29 | 2018-10-04 | Azura Ophthalmics Ltd. | Agents for increasing meibomian gland lipid secretion |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| AU2020259997B2 (en) | 2019-04-18 | 2025-08-07 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2020212755A1 (en) | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CA3196145A1 (en) | 2020-10-21 | 2022-04-28 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2020
- 2020-04-16 WO PCT/IB2020/000288 patent/WO2020212755A1/en not_active Ceased
- 2020-04-16 AU AU2020259996A patent/AU2020259996B2/en not_active Expired - Fee Related
- 2020-04-16 EP EP20791787.3A patent/EP3955926A4/en active Pending
- 2020-04-16 CA CA3137583A patent/CA3137583A1/en active Pending
- 2020-04-16 KR KR1020217037591A patent/KR20220003555A/ko not_active Ceased
- 2020-04-16 CN CN202080044807.9A patent/CN114025759A/zh active Pending
- 2020-04-16 JP JP2021559917A patent/JP7700045B2/ja active Active
- 2020-06-17 US US16/904,036 patent/US10875845B2/en active Active
- 2020-12-04 US US17/112,371 patent/US11634411B2/en active Active
-
2021
- 2021-10-14 IL IL287264A patent/IL287264A/en unknown
-
2023
- 2023-03-08 US US18/119,248 patent/US20230357207A1/en active Pending
-
2025
- 2025-11-07 US US19/382,548 patent/US20260234132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5524181B2 (ja) | 治療剤としての置換ガンマラクタム | |
| JP2022529315A5 (cg-RX-API-DMAC10.html) | ||
| JP2020521767A5 (cg-RX-API-DMAC10.html) | ||
| JP6270848B2 (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| JP2012525437A5 (cg-RX-API-DMAC10.html) | ||
| JP2011507878A5 (cg-RX-API-DMAC10.html) | ||
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2022509206A5 (cg-RX-API-DMAC10.html) | ||
| JP2023512823A5 (cg-RX-API-DMAC10.html) | ||
| US9150537B2 (en) | Bicyclic compound and use thereof for medical purposes | |
| KR20130029049A (ko) | 아데노신 화합물 및 이의 용도 | |
| JP2016513707A (ja) | 眼神経保護を与える方法 | |
| EP0777669A1 (en) | 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent | |
| RU2019111188A (ru) | Кетоновые ингибиторы лизин-специфичного гингипаина | |
| JP2011515406A (ja) | 治療用の置換シクロペンタン類 | |
| JP2004506010A5 (cg-RX-API-DMAC10.html) | ||
| WO2005007161A1 (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP2011518834A (ja) | 治療剤としての置換ガンマラクタム | |
| JP2011515409A (ja) | 治療用化合物 | |
| JP5254007B2 (ja) | 置換β−ラクタム及び医薬におけるその使用 | |
| DK3107906T3 (en) | REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE | |
| JP2001515897A (ja) | トロンボキサンリガンド | |
| JP2024538954A (ja) | 皮膚および眼の障害を処置するための化合物および方法 | |
| WO2021145355A1 (ja) | 近視の治療、近視の予防および/または近視の進行抑制のための医薬組成物 |